May 2026 Catalent expanded its pharmaceutical contract manufacturing and research capabilities by investing in advanced biologics, cell and gene therapy, and drug development manufacturing facilities.
March 2026 Lonza expanded its contract development and manufacturing organization (CDMO) services by increasing capabilities for biologics, small molecules, and advanced therapy manufacturing.
December 2025 Thermo Fisher Scientific expanded its Patheon pharmaceutical services portfolio by strengthening drug development, clinical trial manufacturing, and commercial production capabilities.
September 2025 Samsung Biologics expanded its biopharmaceutical contract manufacturing capacity by investing in large-scale production facilities and advanced biologics manufacturing technologies.